At Simulations Plus, we stand with the Black community against racial discrimination, violence, and injustice. We are committed to diversity and inclusion in our workplace and re-doubling our efforts in support of these objectives within our organization and in the community we serve.
Simulations Plus Acquires Lixoft, Expanding Modeling Software Offerings and Broadening Presence in Europe
Dr. Paul B. Watkins and Dr. Jeff Woodhead discuss the DILIsym analysis of the latest publication in Toxicological Sciences!
Simulations Plus announced today the launch of its COVID-19 ACT Program to provide expedited, expert consulting assistance in coronavirus research.
Our goal is to help our clients minimize or eliminate the questions posed by regulatory reviews while decreasing the cost and time it takes to develop detailed reports.
To improve the productivity of science-based research & development enterprises by delivering innovative modeling and simulation software and insightful consulting services.
Providing strategic pharmacology and pharmacometric consulting services, PK/PD model development with NONMEM, clinical trial simulations, exposure-response evaluations, dose justification strategies and related data management services.
Ensuring the safety of drug therapies by leveraging our expertise in the areas of drug-induced liver injury, metabolic diseases, and modeling and simulation.
Lixoft products are designed to save the time and energy of pharmacometricians and biostatisticianby bringing breakthrough advances to the modeling & simulation community in user-friendly tools.
Stay up-to-date with our upcoming conference attendance & presentations, application webinars, and training workshop courses.
Find out how your peers are applying our technology by reviewing journal articles describing various user case studies.